
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Med Sci (Basel)</journal-id><journal-id journal-id-type="publisher-id">medsci</journal-id><journal-title-group><journal-title>Medical Sciences</journal-title></journal-title-group><issn pub-type="epub">2076-3271</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29890705</article-id><article-id pub-id-type="pmc">6024798</article-id><article-id pub-id-type="doi">10.3390/medsci6020049</article-id><article-id pub-id-type="publisher-id">medsci-06-00049</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)? CON</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9600-3537</contrib-id><name><surname>Marcos</surname><given-names>Pedro J</given-names></name><xref ref-type="aff" rid="af1-medsci-06-00049">1</xref><xref rid="c1-medsci-06-00049" ref-type="corresp">*</xref><xref ref-type="aff" rid="af1-medsci-06-00049">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez-Campos</surname><given-names>Jos&#x000e9; Luis</given-names></name><xref ref-type="aff" rid="af2-medsci-06-00049">2</xref><xref ref-type="aff" rid="af3-medsci-06-00049">3</xref></contrib></contrib-group><aff id="af1-medsci-06-00049"><label>1</label>Direcci&#x000f3;n de Procesos Asistenciales, Servicio de Neumolog&#x000ed;a, Instituto de Investigaci&#x000f3;n Biom&#x000e9;dica de A Coru&#x000f1;a (INIBIC), Complejo Hospitalario Universitario de A Coru&#x000f1;a (CHUAC), Estructura Organizativa de Xerencia de Xesti&#x000f3;n Integrada (EOXI) de A Coru&#x000f1;a Sergas, Universidade da Coru&#x000f1;a (UDC),15006 A Coru&#x000f1;a, Spain</aff><aff id="af2-medsci-06-00049"><label>2</label>Unidad M&#x000e9;dico-Quir&#x000fa;rgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc&#x000ed;o/Universidad de Sevilla, 41013 Seville, Spain; <email>lcampos@separ.es</email></aff><aff id="af3-medsci-06-00049"><label>3</label>Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain</aff><author-notes><corresp id="c1-medsci-06-00049"><label>*</label>Correspondence: <email>pedro.jorge.marcos.rodriguez@sergas.es</email>; Tel.: +34-981-178-000; Fax: +34-981-178-001</corresp><fn id="fn1-medsci-06-00049"><label>&#x02020;</label><p>Current Address: Direcci&#x000f3;n M&#x000e9;dica, Hospital de A Coru&#x000f1;a, As Xubias de Arriba 84, 15006 A Coru&#x000f1;a, Spain</p></fn></author-notes><pub-date pub-type="epub"><day>08</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2018</year></pub-date><volume>6</volume><issue>2</issue><elocation-id>49</elocation-id><history><date date-type="received"><day>18</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>07</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The employment of systemic corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD) has been shown to improve airway limitation, decrease treatment failure and risk of relapse, and may improve symptoms in addition to decreasing the length of hospital stay. Nowadays, all clinical guidelines recommend systemic corticosteroids to treat moderate or severe COPD exacerbations. However, their use is associated with potential side effects, mainly hyperglycemia. In the era of precision medicine, the possibility of employing blood eosinophil count has emerged as a potential way of optimizing therapy. Issues regarding the intra-individual variability of blood eosinophil count determination, a lack of clear data regarding the real prevalence of eosinophilic acute exacerbations, the fact that previously published studies have demonstrated the benefit of systemic corticosteroids irrespective of eosinophil levels, and especially the fact that there is only one well-designed study justifying this approach have led us to think that we are not ready to use eosinophil count to guide treatment with systemic corticosteroids during acute exacerbations of COPD.</p></abstract><kwd-group><kwd>Chronic obstructive pulmonary disease (COPD)</kwd><kwd>acute exacerbation</kwd><kwd>eosinophil</kwd><kwd>precision medicine</kwd><kwd>systemic corticosteroids</kwd></kwd-group></article-meta></front><body><sec id="sec1-medsci-06-00049"><title>1. Introduction</title><p>Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide [<xref rid="B1-medsci-06-00049" ref-type="bibr">1</xref>]. The course of COPD is characterized by episodes of increased symptoms known as exacerbations that, when severe enough, regularly require additional treatments. Exacerbations contribute to a long-term decline in lung function [<xref rid="B2-medsci-06-00049" ref-type="bibr">2</xref>], reduced physical activity [<xref rid="B3-medsci-06-00049" ref-type="bibr">3</xref>] and also have a significant and long-lasting effect on quality of life [<xref rid="B4-medsci-06-00049" ref-type="bibr">4</xref>]. Patients with repeated exacerbations or with exacerbations that require hospitalization have been associated with an increased risk of morbidity and mortality [<xref rid="B2-medsci-06-00049" ref-type="bibr">2</xref>,<xref rid="B5-medsci-06-00049" ref-type="bibr">5</xref>,<xref rid="B6-medsci-06-00049" ref-type="bibr">6</xref>]. Although those with less severe exacerbations are often managed as outpatients, COPD exacerbations may require hospitalization. Although the treatment of exacerbations is a significant contributor to the economic burden of COPD [<xref rid="B7-medsci-06-00049" ref-type="bibr">7</xref>], COPD hospitalization is what most contributes to the global cost of the disease [<xref rid="B8-medsci-06-00049" ref-type="bibr">8</xref>,<xref rid="B9-medsci-06-00049" ref-type="bibr">9</xref>].</p></sec><sec id="sec2-medsci-06-00049"><title>2. Systemic Corticosteroids in COPD Exacerbation</title><p>Chronic obstructive pulmonary disease exacerbation treatment aims to minimize the impact of the current exacerbation and prevent the development of subsequent events. Most COPD exacerbations can be safely managed in the outpatient setting. The main intervention consists of optimizing bronchodilation by increasing the dose and frequency of bronchodilators [<xref rid="B10-medsci-06-00049" ref-type="bibr">10</xref>]. The other two key points are antibiotics and systemic corticosteroid treatment.</p><p>Although previously published data already suggested the potential benefit of systemic corticosteroids when treating patients with an acute exacerbation of COPD [<xref rid="B11-medsci-06-00049" ref-type="bibr">11</xref>,<xref rid="B12-medsci-06-00049" ref-type="bibr">12</xref>], it was the publication of a randomized trial by Niewoehner et al. [<xref rid="B13-medsci-06-00049" ref-type="bibr">13</xref>] in 1999 which highlighted the importance of this treatment. They compared two regimens of systemic corticosteroids (SC, 2 or 8 weeks) versus a placebo and demonstrated that treatment with SC resulted in improved clinical outcomes (less treatment failure, shorter hospital stays and better lung function). It was also observed that the maximum benefit was obtained in the first two weeks of treatment. Based on these and new results [<xref rid="B14-medsci-06-00049" ref-type="bibr">14</xref>], systemic corticosteroids were cemented as a cornerstone of therapy for these patients.</p><p>Some years later, Aaron et al. [<xref rid="B15-medsci-06-00049" ref-type="bibr">15</xref>] studied the effectiveness of oral prednisone in reducing the risks of relapse after an outpatient exacerbation of COPD. They selected patients discharged from the emergency room who were randomized to receive 10 days of treatment of prednisone or placebo. They found a lower rate of relapse at 30 days (27% vs. 43%; <italic>p</italic> = 0.05), longer time spent relapse-free at 30 days (<italic>p</italic> = 0.04) and a non-significant reduction in hospitalizations for COPD (11% vs. 21%; <italic>p</italic> = 0.11). They also found that after 10 days of treatment, patients treated with systemic corticosteroids had greater improvements in lung function, less dyspnea and better quality of life based on the determinations of the chronic respiratory disease questionnaire (CRQ).</p><p>Since those cornerstone studies, new data has reinforced the effect of the treatment (sometimes being compared with steroid nebulized therapy [<xref rid="B14-medsci-06-00049" ref-type="bibr">14</xref>,<xref rid="B16-medsci-06-00049" ref-type="bibr">16</xref>]) and another studies even have questioned the effect in new hospital settings, like the intensive care unit (ICU) [<xref rid="B17-medsci-06-00049" ref-type="bibr">17</xref>]. A Cochrane Review published in 2014 confirmed the benefit of systemic corticosteroids in preventing treatment failure versus placebo (odds ratio (OR) 0.49; 95% confidence interval (CI), 0.35&#x02013;0.67) [<xref rid="B18-medsci-06-00049" ref-type="bibr">18</xref>] with high quality evidence resulting in a number of patients needed to treat to avoid one treatment failure of nine. There was moderate-quality evidence for a lower rate of relapse by one month for treatment with systemic corticosteroids (hazard ratio (HR) 0.78; 95% CI 0.63 to 0.97), better lung function, especially in the first three days (mean difference (MD) 140 mL; 95% CI, 90 to 200), and shorter hospitalization for the inpatient (MD -&#x02212;1.22 days; 95% CI, &#x02212;2.26 to &#x02212;0.18). However, mortality up to 30 days was not reduced by treatment with systemic corticosteroids compared with the control in 12 studies (<italic>n</italic> = 1319; OR 1.00; 95% CI, 0.60 to 1.66), and the likelihood of adverse events, particularly hyperglycemia, increased with corticosteroid (CS) treatment (OR 2.33; 95% CI, 1.59 to 3.43), with a number of patients needed to harm of 6 (95% CI 4 to 10).</p><p>The last robust and well-designed study regarding the impact of SC on COPD exacerbations was perhaps the &#x0201c;Reduce trial&#x0201d;, published by Leuppi et al. in JAMA in 2013 [<xref rid="B19-medsci-06-00049" ref-type="bibr">19</xref>]. In this study, patients arriving at the emergency department with acute exacerbations of COPD were randomized in order to detect whether five-day treatment with systemic glucocorticoids was non-inferior to 14-day treatment with regard to re-exacerbation within six months of follow-up. The study was positive, demonstrating non-inferior results with the short course, although with significantly reduced glucocorticoid exposure. A review of the most relevant studies regarding the efficacy of systemic corticosteroids can be seen in <xref rid="medsci-06-00049-t001" ref-type="table">Table 1</xref>.</p><sec><title>Guideline Recommendations</title><p>Nowadays, all clinical guidelines recommend systemic corticosteroids to treat moderate or severe COPD exacerbations. Recommendations regarding this issue have been changing in parallel to the development of new studies (<xref rid="medsci-06-00049-t002" ref-type="table">Table 2</xref>). Systemic corticosteroids treatment was already recommended in the first Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary, published in 2001. Systemic corticosteroids were recommended as an addition to bronchodilator therapy, especially in the hospital management of acute exacerbations of COPD with level A evidence. There were doubts about the exact dosage, even when it was highlighted that high doses were associated with a significant risk of side effects. Finally, 30 to 40 mg of oral prednisolone daily for 10 to 14 days was considered a &#x0201c;reasonable&#x0201d; compromise between efficacy and safety. This recommendation was based on level D evidence, pointing out that prolonged treatment does not result in greater efficacy and increases the risk of side effects.</p><p>During subsequent updates to the GOLD Guidelines, evidence regarding the dosage and duration was progressively changed from higher to lower doses and duration. As a result, in GOLD 2006, there was level C evidence for treatment with 30&#x02013;40 mg of prednisone a day for seven to ten days, and in GOLD 2014, after the publication of the REDUCE (reduction in the use of corticosteroids in exacerbated COPD) [<xref rid="B19-medsci-06-00049" ref-type="bibr">19</xref>] results, the recommendation changed to treatment for five days with a dosage of 40 mg a day, with B level evidence. The 2014 update was the first time that GOLD suggested that nebulized corticosteroids (budesonide) alone may be an alternative to oral corticosteroids in the treatment of exacerbations. The last prominent GOLD recommendations regarding treatment with systemic corticosteroids were published in the 2017 edition, suggesting for the first time that systemic corticosteroids may be less efficacious in treating acute COPD exacerbations in patients with lower blood eosinophil levels.</p></sec></sec><sec id="sec3-medsci-06-00049"><title>3. The Need for Phenotyping Exacerbations and the Potential of Eosinophils</title><sec id="sec3dot1-medsci-06-00049"><title>3.1. Precision Medicine and COPD Exacerbations</title><p>In the current era of precision medicine [<xref rid="B23-medsci-06-00049" ref-type="bibr">23</xref>], COPD is increasingly recognized as being comprised of various phenotypes [<xref rid="B24-medsci-06-00049" ref-type="bibr">24</xref>,<xref rid="B25-medsci-06-00049" ref-type="bibr">25</xref>]. Phenotyping has identified options for targeted therapy, aiming to treat each patient according to his or her own characteristics [<xref rid="B26-medsci-06-00049" ref-type="bibr">26</xref>]. Biomarkers that could predict treatment responses to anti-inflammatory drugs may be useful in optimizing the benefit versus risk ratio. There has been more interest regarding the possibility of phenotyping exacerbations since the 2011 publication by Bafadhel et al. [<xref rid="B27-medsci-06-00049" ref-type="bibr">27</xref>], in which they showed that there were biologic COPD exacerbation clusters that are clinically indistinguishable and that biomarkers can be used to identify specific clinical phenotypes during exacerbations of COPD. In this study, authors could differentiate four distinct biologic exacerbation clusters: bacterial, viral, pauci-inflammatory and eosinophilic. Interestingly, the four different exacerbation types were the result of a mathematical model based on cluster and principal component analyses, and the crude data presented a clear overlap between the different types. Later that year, Gao et al. [<xref rid="B28-medsci-06-00049" ref-type="bibr">28</xref>] also identified four exacerbation types according to cell distribution in sputum. After a lifetime of knowing but not noticing its potential, the eosinophil, specifically the blood count, has now taken center stage as the most clinically accessible biomarker to aid in the management of COPD.</p></sec><sec id="sec3dot2-medsci-06-00049"><title>3.2. Eosinophilia Associated with COPD</title><p>Ever since studies in the early nineties [<xref rid="B29-medsci-06-00049" ref-type="bibr">29</xref>] suggested that exacerbations of chronic bronchitis were associated with marked airway eosinophilia, eosinophilic airway inflammation has been classically associated with asthma. Since airway eosinophilia is a reliable predictor of responsiveness to inhaled [<xref rid="B30-medsci-06-00049" ref-type="bibr">30</xref>] and systemic corticosteroids treatment [<xref rid="B31-medsci-06-00049" ref-type="bibr">31</xref>,<xref rid="B32-medsci-06-00049" ref-type="bibr">32</xref>,<xref rid="B33-medsci-06-00049" ref-type="bibr">33</xref>], its determination seems crucial for better management of these patients. </p><p>Sputum eosinophil count has been postulated as the best non-invasive way of detecting eosinophilic airway inflammation. However, its measurement has some intrinsic problems including moderate repeatability (intra-class coefficient of 0.49 at 12 weeks [<xref rid="B34-medsci-06-00049" ref-type="bibr">34</xref>]) and primarily because it is time consuming, requires certain expertise, and because some patients do not provide adequate samples for analysis or do not provide point-of-care results [<xref rid="B35-medsci-06-00049" ref-type="bibr">35</xref>]. As a result, blood eosinophil count appears to be a more practical approach. There has been significant interest in the role of blood eosinophil count in COPD, especially in predicting responses to inhaled corticosteroid therapy exacerbation rates, mostly from the studies showing that the higher the blood eosinophil count, the greater the benefit in reducing exacerbations [<xref rid="B36-medsci-06-00049" ref-type="bibr">36</xref>,<xref rid="B37-medsci-06-00049" ref-type="bibr">37</xref>].</p></sec><sec id="sec3dot3-medsci-06-00049"><title>3.3. Blood Eosinophil-Guided Systemic Corticosteroids for Exacerbations of COPD, the Evidence to Date</title><p>The predictive role of peripheral blood eosinophil counts as a surrogate biomarker of eosinophilic airway inflammation as a means to direct therapy during exacerbations was recently hypothesized [<xref rid="B27-medsci-06-00049" ref-type="bibr">27</xref>]. Some data supporting this approach are that treatment responses to systemic corticosteroids are heterogeneous or do not impact tough clinical outcomes like mortality [<xref rid="B18-medsci-06-00049" ref-type="bibr">18</xref>]. However, one of the most important concerns regarding this treatment it is that systemic corticosteroids treatment is associated with significant side effects as hyperglycemia, deep vein thrombosis, weight gain, osteoporosis, infections or neuropsychiatric disorders [<xref rid="B13-medsci-06-00049" ref-type="bibr">13</xref>,<xref rid="B38-medsci-06-00049" ref-type="bibr">38</xref>,<xref rid="B39-medsci-06-00049" ref-type="bibr">39</xref>]). Even short oral corticosteroids courses have been associated with those side effects [<xref rid="B39-medsci-06-00049" ref-type="bibr">39</xref>], and the effect is added when patients receive multiple steroids courses when suffering relapsing processes. All of these questions have made some authors to have focused on eosinophil as the cornerstone to guide COPD exacerbation treatment.</p><p>Reading carefully some studies regarding this issue, it seems that there is some evidence between patients who responded very well to systemic steroids and another who did not. For example, in the Aaron study [<xref rid="B15-medsci-06-00049" ref-type="bibr">15</xref>] the absolute reduction in risk of relapse at 30 days was 16% with a <italic>p</italic> value of 0.05, but 95% confidence interval was between 0 and 32% or the absolute reduction in risk of hospitalization was 10%, but again with a CI from &#x02212;2 to 22. So, can eosinophil be the biomarker that could help us to discriminate potential &#x0201c;responders&#x0201d;? </p><p>To date, only one study has shown that a biomarker-directed strategy (eosinophil count) can be safely used with good clinical results to guide prescription in COPD exacerbations [<xref rid="B40-medsci-06-00049" ref-type="bibr">40</xref>]. The Bafadhel group [<xref rid="B39-medsci-06-00049" ref-type="bibr">39</xref>] selected 164 patients, 109 of whom suffered an exacerbation and were randomized to a standard arm, where they received systemic corticosteroids for two weeks, or a biomarker-directed arm, where only patients with a blood eosinophil count of &#x02265;2% received systemic corticosteroids while the others received placebo. The main outcome of the study was the non-inferiority in health status using the chronic respiratory questionnaire (CRQ), the equivalence of the proportion of treatment failure, and evidence of a reduction in CS exposure in the biomarker-directed study group. The results of the study were positive since CRQ improvement in the standard arm was similar to the biomarker-directed group (0.8 vs. 1.1, MD, 0.3; CI 95% 0.0&#x02013;0.06; <italic>p</italic> = 0.05) and there were no differences in treatment failure (13% vs. 5%; 95% CI, &#x02212;1 to 16; <italic>p</italic> = 0.07). There was also less exposure to systemic corticosteroids in the biomarker study group since 49% of the exacerbations did not receive systemic corticosteroids. Furthermore, it was found that in biomarker-negative exacerbations, those patients treated with systemic corticosteroids had 15% treatment failures compared with only 2% of those given placebo (<italic>p</italic> = 0.04).</p><p>The same group completed a further analysis [<xref rid="B41-medsci-06-00049" ref-type="bibr">41</xref>] of randomized controlled studies comparing outcomes for patients with COPD exacerbations treated with prednisolone vs. non-prednisolone (placebo or equivalent). Of just six studies which fulfilled the criteria, only three of them had blood eosinophil count available at the onset of the exacerbation. After analyzing a total of 243 patients (95 patients with 107 exacerbations in the non-prednisolone group vs. 148 patients with 193 exacerbations in the prednisolone group), the study showed that patients presenting with an acute COPD exacerbation and a peripheral eosinophil blood count &#x02265;2% had a significantly reduced treatment failure rate compared with the placebo group (20% vs. 45%; <italic>p</italic> &#x0003c; 0.001).</p></sec></sec><sec id="sec4-medsci-06-00049"><title>4. Are We Ready to Use Eosinophil Count to Guide Treatment with Systemic Corticosteroids During Acute Exacerbations of COPD? Not Yet</title><p>There are some concerns regarding this question which should better be addressed before taking the step to treat patients in this new way.</p><sec id="sec4dot1-medsci-06-00049"><title>4.1. Can Eosinophils be Trusted in Clinical Practice</title><p>Moving on from the role sputum eosinophilia plays in clinical practice due to the problems explained above, there are concerns regarding the use of blood count eosinophilia in the clinical setting. Although it has been proven that there is good agreement between two blood eosinophil count measurements of over a median of 28 days (Ri, intra-class correlation coefficient = 0.8; 95% CI: 0.66&#x02013;0.88; <italic>p</italic> &#x0003c; 0.001) or even over 1 year (Ri, 0.64), these results represent an average of group results, and when managing individual patients and making decisions based on these results in clinical practice, the benefit may not be so obvious. There is significant intra-subject variability with the peripheral blood eosinophil test, and there are a number of factors that contribute to within-subject variability of blood eosinophil measurements, particularly those that lower the count and could lead to a false negative test [<xref rid="B42-medsci-06-00049" ref-type="bibr">42</xref>]. Blood eosinophil counts have been described to vary with exercise, food or medications. There is also a significant diurnal variability of blood eosinophil count with peak levels recorded around midnight and lowest levels at midday and a within-subject biological variation in hourly eosinophil count of 20.9% has been described. Furthermore, although a good correlation between sputum and eosinophilia has recently been suggested, a recent major study based on the SPIROMICS cohort analysis found that blood eosinophils alone showed a significant but weak association with sputum eosinophil counts (receiver operating characteristic area under the curve of 0&#x000b7;64, <italic>p</italic> &#x0003c; 0.0001) with a high false-discovery rate of 72%. It has also been shown to not be a reliable biomarker for COPD severity, exacerbations or sputum eosinophils [<xref rid="B43-medsci-06-00049" ref-type="bibr">43</xref>]. This data needs to be taken into account, since SPIROMICS is the largest prospective study to date to have investigated sputum and blood eosinophil counts and their association with clinical outcomes in a population at low risk of exacerbation [<xref rid="B44-medsci-06-00049" ref-type="bibr">44</xref>]. Furthermore, there are subtypes of eosinophils that are indistinguishable with the usual hematological stains.</p></sec><sec id="sec4dot2-medsci-06-00049"><title>4.2. How Many Patients Could Benefit from This Approach</title><p>It is not clear what the optimal cut-off point is for blood eosinophils. In the Bafadhel study [<xref rid="B27-medsci-06-00049" ref-type="bibr">27</xref>], a cut-off at 2% of blood eosinophil counts distinguishes between eosinophilic and non-eosinophilic COPD exacerbation with a 90% sensitivity. Thus, most studies have adopted this cut-off value. However, even if we take an eosinophil level of 2% as valid, there are not many studies that have investigated the prevalence of eosinophilia on top of an exacerbation. Most of the data (<xref rid="medsci-06-00049-t003" ref-type="table">Table 3</xref>) came from retrospective studies, with a wide range of prevalence (9.6 to 40%), and different cut-off points (&#x0003e;2%, &#x02265;2%), absolute number of eosinophils, etc. [<xref rid="B45-medsci-06-00049" ref-type="bibr">45</xref>,<xref rid="B46-medsci-06-00049" ref-type="bibr">46</xref>,<xref rid="B47-medsci-06-00049" ref-type="bibr">47</xref>,<xref rid="B48-medsci-06-00049" ref-type="bibr">48</xref>,<xref rid="B49-medsci-06-00049" ref-type="bibr">49</xref>]. The fact that the eosinophil count is known to fall by &#x0003e;50% within the first four hours following systemic corticosteroids administration [<xref rid="B50-medsci-06-00049" ref-type="bibr">50</xref>] and the retrospective nature of these studies highlighted a potential confounding bias arising from the real prevalence of systemic corticosteroids administration in severe eosinophilic COPD. Ultimately, there really isn&#x02019;t any data regarding the real role of the eosinophil on community exacerbations of COPD.</p></sec><sec id="sec4dot3-medsci-06-00049"><title>4.3. Did Previous Studies Supporting the Use of Systemic Corticosteroids Measure the Eosinophil Count</title><p>There is no doubt regarding the beneficial results of employing systemic corticosteroids to treat COPD exacerbations [<xref rid="B18-medsci-06-00049" ref-type="bibr">18</xref>]. Most of the papers that justified their use did not show results regarding the eosinophil count, at least the most robust ones [<xref rid="B13-medsci-06-00049" ref-type="bibr">13</xref>,<xref rid="B15-medsci-06-00049" ref-type="bibr">15</xref>,<xref rid="B19-medsci-06-00049" ref-type="bibr">19</xref>,<xref rid="B51-medsci-06-00049" ref-type="bibr">51</xref>]. We do not know if it is because they did not collect the data or they simply did not show it. The point is that those studies demonstrated a positive outcome for systemic corticosteroids independent of eosinophil count levels and, based on their randomized designs, it is expected that eosinophilic and non-eosinophilic patients had been properly distributed between the study arms.</p><p>Interestingly, for treatment selection we would like to have a highly predictive negative value to discard candidates or, the other way around, to have a highly positive predictive value to select candidates for therapy. 2% is a low limit so probably the philosophy behind is that of selecting non-responders. In any case, when a higher limit is defined we will then always have a level of uncertainty with middle values, which allows this biomarker to be used in a selection of patients.</p></sec><sec id="sec4dot4-medsci-06-00049"><title>4.4. Any Light at the End of the Tunnel</title><p>The 2017 GOLD guidelines recommendation states that, &#x0201c;Recent studies suggest that glucocorticoids may be less efficacious in treating acute COPD exacerbations in patients with lower levels of blood eosinophils.&#x0201d; To date, it is only based on the 109 patients and 166 exacerbation events in the Bafadhel study [<xref rid="B40-medsci-06-00049" ref-type="bibr">40</xref>] we mentioned before, and it appears that in order to make such a strong recommendation leading to a change in the clinical practice in so many patients, further studies and evidence in more patients would be necessary. Although it is a very well-designed study, it does have some limitations (in addition to sample size) that have to be pointed out which could question the recommendation. Firstly, only 10 patients in that cohort suffered from a severe exacerbation, so the application of the eosinophil count to guide treatment with systemic corticosteroids during acute exacerbations of COPD that require hospitalization is not clear and would need more data to be clearly recommended. Secondly, all patients in the study received antibiotics. Although this methodology could be justified in order to replicate the methods employed in the systemic corticosteroids studies where most of the patients received also antibiotics, we would like to highlight that in real clinical setting antibiotic decisions are based on Anthonisen criteria in moderate exacerbations. Thirdly, all of the patients that participated in the study had to have a prior history of exacerbations. We do not know if this approach could be applied to patients with infrequent exacerbations since we do not know if that characteristic could be related to a different therapeutic response. Finally, there is a methodological concern due to the fact that this study applied randomization by minimization which, while a good approach for randomized patients within a small sample size, also has some limitations [<xref rid="B52-medsci-06-00049" ref-type="bibr">52</xref>]. Compared with a simple randomization where the allocation of future patients to a trial cannot be predicted, minimization has the disadvantage that, in certain cases, the next allocation can be predicted with certainty with knowledge of the characteristics of earlier patients. There is therefore a potential for selection bias, which can affect the validity of a trial&#x02019;s results. Even knowing which allocation is more likely to occur next can result in selection bias.</p><p>Although no new studies have been published, there is an ongoing, multi-center, randomized, controlled, open-label trial [<xref rid="B53-medsci-06-00049" ref-type="bibr">53</xref>] which will help to better address this question. Authors will randomize over 300 patients to test if standard care compared to eosinophil-guided systemic corticosteroids -sparing therapy is non-inferior regarding length of hospital stay (primary outcome). This is expected to answer the uncertainties of Bafadhel&#x000b4;s study as, because patients of the study are admitted to the hospital, patients with and without history of previous exacerbations were included and it has a bigger sample size.</p></sec></sec><sec id="sec5-medsci-06-00049"><title>5. Is it Realistic for These Recommendations to be Implemented in Clinical Practice in the Short Term</title><p>Although the GOLD general recommendation of employing short-term systemic corticosteroids regimens to treat COPD acute exacerbations were first recommended in 2006, when a regimen of 30&#x02013;40 mg of prednisone was recommended for 7&#x02013;10 days, and this recommendation was re-adapted in GOLD 2014 based on the REDUCE Trial [<xref rid="B19-medsci-06-00049" ref-type="bibr">19</xref>] to 40 mg a day for five days, the application in clinical practice is lacking [<xref rid="B37-medsci-06-00049" ref-type="bibr">37</xref>,<xref rid="B54-medsci-06-00049" ref-type="bibr">54</xref>,<xref rid="B55-medsci-06-00049" ref-type="bibr">55</xref>,<xref rid="B56-medsci-06-00049" ref-type="bibr">56</xref>,<xref rid="B57-medsci-06-00049" ref-type="bibr">57</xref>,<xref rid="B58-medsci-06-00049" ref-type="bibr">58</xref>]. Our group recently published a study where we detected that most of the patients admitted to the hospital with a COPD exacerbation did not receive systemic corticosteroids therapy according to guidelines, this patients received more dosages and more days than recommended, and this was associated with a prolonged hospital stay [<xref rid="B54-medsci-06-00049" ref-type="bibr">54</xref>]. As a result, it is a long road of unknown duration from the time Guidelines recommend a change until it is generally accepted and employed.</p><p>Another question that has to be taken into account is that, by definition, a blood sample is required. This does not pose any problem in the patients who are admitted to the hospital or who consult an emergency service. However, this can be a problem in outpatient clinics, and specially in primary care where there is usually a large volume of patients and urgent analysis cannot always be done, showing a probably lack of potential application as a practical test of this approach in this setting. Even more, the new approach suggested by the study by Sivapalan et al. [<xref rid="B53-medsci-06-00049" ref-type="bibr">53</xref>], where the discontinuation of systemic corticosteroids would be based on a daily blood eosinophil test analysis, argues that this approach could go against clinical practice in the hospital setting.</p><p>Although nowadays most COPD patients who suffer from severe COPD exacerbations are elderly people with significant comorbidity and are likely have decreased immunity [<xref rid="B59-medsci-06-00049" ref-type="bibr">59</xref>], systemic steroids have been associated with positive outcomes. </p></sec><sec id="sec6-medsci-06-00049"><title>6. Conclusions</title><p>Systemic corticosteroids have been shown to improve clinical outcomes in the treatment of COPD exacerbations. However, their use is associated with potential side effects. In the era of precision medicine, the possibility of employing blood eosinophil count has appeared as a potential way to optimize therapy. Nevertheless, there are few clinical trials focused on properly addressing the question and more clinical data is needed.</p></sec></body><back><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-medsci-06-00049"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Global Initiative for Chronic Obstructive Lung Disease, Executive and Science Commitees</collab></person-group><source>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease</source><publisher-name>Global Initiative for Chronic Obstructive Lung Disease, Executive and Science Commitees</publisher-name><year>2014</year></element-citation></ref><ref id="B2-medsci-06-00049"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>G.C.</given-names></name><name><surname>Seemungal</surname><given-names>T.A.R.</given-names></name><name><surname>Bhowmik</surname><given-names>A.</given-names></name><name><surname>Wedzicha</surname><given-names>J.A.</given-names></name></person-group><article-title>Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>2002</year><volume>57</volume><fpage>847</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1136/thorax.57.10.847</pub-id><pub-id pub-id-type="pmid">12324669</pub-id></element-citation></ref><ref id="B3-medsci-06-00049"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>G.C.</given-names></name><name><surname>Wilkinson</surname><given-names>T.M.A.</given-names></name><name><surname>Hurst</surname><given-names>J.R.</given-names></name><name><surname>Perera</surname><given-names>W.R.</given-names></name><name><surname>Wedzicha</surname><given-names>J.A.</given-names></name></person-group><article-title>Exacerbations and time spent outdoors in chronic obstructive pulmonary disease</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2005</year><volume>171</volume><fpage>446</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1164/rccm.200408-1054OC</pub-id><pub-id pub-id-type="pmid">15579723</pub-id></element-citation></ref><ref id="B4-medsci-06-00049"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>T.M.A.</given-names></name><name><surname>Donaldson</surname><given-names>G.C.</given-names></name><name><surname>Hurst</surname><given-names>J.R.</given-names></name><name><surname>Seemungal</surname><given-names>T.A.R.</given-names></name><name><surname>Wedzicha</surname><given-names>J.A.</given-names></name></person-group><article-title>Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2004</year><volume>169</volume><fpage>1298</fpage><lpage>1303</lpage><pub-id pub-id-type="pmid">14990395</pub-id></element-citation></ref><ref id="B5-medsci-06-00049"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soler-Cataluna</surname><given-names>J.J.</given-names></name><name><surname>Mart&#x000ed;nez-Garc&#x000ed;a</surname><given-names>M.&#x000c1;.</given-names></name><name><surname>Rom&#x000e1;n S&#x000e1;nchez</surname><given-names>P.</given-names></name><name><surname>Salcedo</surname><given-names>E.</given-names></name><name><surname>Navarro</surname><given-names>M.</given-names></name><name><surname>Ochando</surname><given-names>R.</given-names></name></person-group><article-title>Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>2005</year><volume>60</volume><fpage>925</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1136/thx.2005.040527</pub-id><pub-id pub-id-type="pmid">16055622</pub-id></element-citation></ref><ref id="B6-medsci-06-00049"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>S.A.J.</given-names></name><name><surname>Johansen</surname><given-names>M.B.</given-names></name><name><surname>Olsen</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Parker</surname><given-names>J.M.</given-names></name><name><surname>Molfino</surname><given-names>N.A.</given-names></name><name><surname>Lash</surname><given-names>T.L.</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>H.T.</given-names></name><name><surname>Christiansen</surname><given-names>C.F.</given-names></name></person-group><article-title>The impact of exacerbation frequency on mortality following acute exacerbations of COPD: A registry-based cohort study</article-title><source>BMJ Open</source><year>2014</year><volume>4</volume><fpage>e006720</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2014-006720</pub-id><pub-id pub-id-type="pmid">25526796</pub-id></element-citation></ref><ref id="B7-medsci-06-00049"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simoens</surname><given-names>S.</given-names></name></person-group><article-title>The economic burden of COPD exacerbations</article-title><source>COPD</source><year>2010</year><volume>7</volume><fpage>159</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.3109/15412555.2010.485098</pub-id><pub-id pub-id-type="pmid">20486812</pub-id></element-citation></ref><ref id="B8-medsci-06-00049"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Bourbeau</surname><given-names>J.</given-names></name></person-group><article-title>Outcomes and health-related quality of life following hospitalization for an acute exacerbation of COPD</article-title><source>Respirology</source><year>2005</year><volume>10</volume><fpage>334</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1843.2005.00718.x</pub-id><pub-id pub-id-type="pmid">15955146</pub-id></element-citation></ref><ref id="B9-medsci-06-00049"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oostenbrink</surname><given-names>J.B.</given-names></name><name><surname>Rutten-van M&#x000f6;lken</surname><given-names>M.P.M.H.</given-names></name></person-group><article-title>Resource use and risk factors in high-cost exacerbations of COPD</article-title><source>Respir. Med.</source><year>2004</year><volume>98</volume><fpage>883</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2004.02.013</pub-id><pub-id pub-id-type="pmid">15338802</pub-id></element-citation></ref><ref id="B10-medsci-06-00049"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedzicha</surname><given-names>J.A.</given-names></name><name><surname>Miravitlles</surname><given-names>M.</given-names></name><name><surname>Calverley</surname><given-names>P.A.</given-names></name><name><surname>Albert</surname><given-names>R.K.</given-names></name><name><surname>Anzueto</surname><given-names>A.</given-names></name><name><surname>Criner</surname><given-names>G.J.</given-names></name><name><surname>Papi</surname><given-names>A.</given-names></name><name><surname>Rabe</surname><given-names>K.F.</given-names></name><name><surname>Rigau</surname><given-names>D.</given-names></name><name><surname>Sliwinski</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Management of COPD exacerbations: A European Respiratory Society/American Thoracic Society guideline</article-title><source>Eur. Respir. J.</source><year>2017</year><volume>49</volume><fpage>1600791</fpage><pub-id pub-id-type="doi">10.1183/13993003.00791-2016</pub-id><pub-id pub-id-type="pmid">28298398</pub-id></element-citation></ref><ref id="B11-medsci-06-00049"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>R.K.</given-names></name><name><surname>Martin</surname><given-names>T.R.</given-names></name><name><surname>Lewis</surname><given-names>S.W.</given-names></name></person-group><article-title>Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency</article-title><source>Ann. Intern. Med.</source><year>1980</year><volume>92</volume><fpage>753</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-92-6-753</pub-id><pub-id pub-id-type="pmid">6770731</pub-id></element-citation></ref><ref id="B12-medsci-06-00049"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullard</surname><given-names>M.J.</given-names></name><name><surname>Liaw</surname><given-names>S.J.</given-names></name><name><surname>Tsai</surname><given-names>Y.H.</given-names></name><name><surname>Min</surname><given-names>H.P.</given-names></name></person-group><article-title>Early corticosteroid use in acute exacerbations of chronic airflow obstruction</article-title><source>Am. J. Emerg. Med.</source><year>1996</year><volume>14</volume><fpage>139</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/S0735-6757(96)90120-5</pub-id><pub-id pub-id-type="pmid">8924134</pub-id></element-citation></ref><ref id="B13-medsci-06-00049"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niewoehner</surname><given-names>D.E.</given-names></name><name><surname>Erbland</surname><given-names>M.L.</given-names></name><name><surname>Deupree</surname><given-names>R.H.</given-names></name><name><surname>Collins</surname><given-names>D.</given-names></name><name><surname>Gross</surname><given-names>N.J.</given-names></name><name><surname>Light</surname><given-names>R.W.</given-names></name><name><surname>Anderson</surname><given-names>P.</given-names></name><name><surname>Morgan</surname><given-names>N.A.</given-names></name></person-group><article-title>Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease</article-title><source>N. Engl. J. Med.</source><year>1999</year><volume>340</volume><fpage>1941</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1056/NEJM199906243402502</pub-id><pub-id pub-id-type="pmid">10379017</pub-id></element-citation></ref><ref id="B14-medsci-06-00049"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maltais</surname><given-names>F.</given-names></name><name><surname>Ostinelli</surname><given-names>J.</given-names></name><name><surname>Bourbeau</surname><given-names>J.</given-names></name><name><surname>Tonnel</surname><given-names>A.B.</given-names></name><name><surname>Jacquemet</surname><given-names>N.</given-names></name><name><surname>Haddon</surname><given-names>J.</given-names></name><name><surname>Rouleau</surname><given-names>M.</given-names></name><name><surname>Boukhana</surname><given-names>M.</given-names></name><name><surname>Martinot</surname><given-names>J.B.</given-names></name><name><surname>Duroux</surname><given-names>P.</given-names></name></person-group><article-title>Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2002</year><volume>165</volume><fpage>698</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.165.5.2109093</pub-id><pub-id pub-id-type="pmid">11874817</pub-id></element-citation></ref><ref id="B15-medsci-06-00049"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaron</surname><given-names>S.D.</given-names></name><name><surname>Vandemheen</surname><given-names>K.L.</given-names></name><name><surname>Hebert</surname><given-names>P.</given-names></name><name><surname>Dales</surname><given-names>R.</given-names></name><name><surname>Stiell</surname><given-names>I.G.</given-names></name><name><surname>Ahuja</surname><given-names>J.</given-names></name><name><surname>Dickinson</surname><given-names>G.</given-names></name><name><surname>Brison</surname><given-names>R.</given-names></name><name><surname>Rowe</surname><given-names>B.H.</given-names></name><name><surname>Dreyer</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>2618</fpage><lpage>2625</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa023161</pub-id><pub-id pub-id-type="pmid">12826636</pub-id></element-citation></ref><ref id="B16-medsci-06-00049"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunen</surname><given-names>H.</given-names></name><name><surname>Hacievliyagil</surname><given-names>S.S.</given-names></name><name><surname>Yetkin</surname><given-names>O.</given-names></name><name><surname>Gulbas</surname><given-names>G.</given-names></name><name><surname>Mutlu</surname><given-names>L.C.</given-names></name><name><surname>In</surname><given-names>E.</given-names></name></person-group><article-title>The role of nebulised budesonide in the treatment of exacerbations of COPD</article-title><source>Eur. Respir. J.</source><year>2007</year><volume>29</volume><fpage>660</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1183/09031936.00073506</pub-id><pub-id pub-id-type="pmid">17251232</pub-id></element-citation></ref><ref id="B17-medsci-06-00049"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abroug</surname><given-names>F.</given-names></name><name><surname>Ouanes-Besbes</surname><given-names>L.</given-names></name><name><surname>Fkih-Hassen</surname><given-names>M.</given-names></name><name><surname>Ouanes</surname><given-names>I.</given-names></name><name><surname>Ayed</surname><given-names>S.</given-names></name><name><surname>Dachraoui</surname><given-names>F.</given-names></name><name><surname>Brochard</surname><given-names>L.</given-names></name><name><surname>Elatrous</surname><given-names>S.</given-names></name></person-group><article-title>Prednisone in COPD exacerbation requiring ventilatory support: An open-label randomised evaluation</article-title><source>Eur. Respir. J.</source><year>2014</year><volume>43</volume><fpage>717</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1183/09031936.00002913</pub-id><pub-id pub-id-type="pmid">23794465</pub-id></element-citation></ref><ref id="B18-medsci-06-00049"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>J.A.E.</given-names></name><name><surname>Tan</surname><given-names>D.J.</given-names></name><name><surname>White</surname><given-names>C.J.</given-names></name><name><surname>Gibson</surname><given-names>P.G.</given-names></name><name><surname>Wood-Baker</surname><given-names>R.</given-names></name><name><surname>Walters</surname><given-names>E.H.</given-names></name></person-group><article-title>Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease</article-title><source>Cochrane Database Syst. Rev.</source><year>2014</year><volume>348</volume><fpage>CD001288</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD001288.pub4</pub-id><pub-id pub-id-type="pmid">25178099</pub-id></element-citation></ref><ref id="B19-medsci-06-00049"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leuppi</surname><given-names>J.D.</given-names></name><name><surname>Schuetz</surname><given-names>P.</given-names></name><name><surname>Bingisser</surname><given-names>R.</given-names></name><name><surname>Bodmer</surname><given-names>M.</given-names></name><name><surname>Briel</surname><given-names>M.</given-names></name><name><surname>Drescher</surname><given-names>T.</given-names></name><name><surname>Duerring</surname><given-names>U.</given-names></name><name><surname>Henzen</surname><given-names>C.</given-names></name><name><surname>Leibbrandt</surname><given-names>Y.</given-names></name><name><surname>Maier</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Short-term vs. Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease</article-title><source>JAMA</source><year>2013</year><volume>309</volume><fpage>2223</fpage><lpage>2229</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.5023</pub-id><pub-id pub-id-type="pmid">23695200</pub-id></element-citation></ref><ref id="B20-medsci-06-00049"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>R.A.</given-names></name><name><surname>Buist</surname><given-names>A.S.</given-names></name><name><surname>Calverley</surname><given-names>P.M.</given-names></name><name><surname>Jenkins</surname><given-names>C.R.</given-names></name><name><surname>Hurd</surname><given-names>S.S.</given-names></name><collab>GOLD Scientific Committee</collab></person-group><source>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease</source><comment>NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary</comment><publisher-name>American Thoracic Society</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2001</year><volume>Volume 163</volume><fpage>1256</fpage><lpage>1276</lpage></element-citation></ref><ref id="B21-medsci-06-00049"><label>21.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Global Initiative for Chronic Obstructive Lung Disease, Executive and Science Commitees</collab></person-group><source>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease</source><publisher-name>Global Initiative for Chronic Obstructive Lung Disease, Executive and Science Commitees</publisher-name><year>2006</year></element-citation></ref><ref id="B22-medsci-06-00049"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Global Initiative for Chronic Obstructive Lung Disease, Executive and Science Commitees</collab></person-group><source>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease</source><publisher-name>Global Initiative for Chronic Obstructive Lung Disease, Executive and Science Commitees</publisher-name><year>2017</year></element-citation></ref><ref id="B23-medsci-06-00049"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>J.R.</given-names></name></person-group><article-title>Precision Medicine in Chronic Obstructive Pulmonary Disease</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2016</year><volume>193</volume><fpage>593</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1164/rccm.201601-0104ED</pub-id><pub-id pub-id-type="pmid">26977962</pub-id></element-citation></ref><ref id="B24-medsci-06-00049"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M.</given-names></name><name><surname>Soler-Catalu&#x000f1;a</surname><given-names>J.J.</given-names></name><name><surname>Calle</surname><given-names>M.</given-names></name><name><surname>Molina</surname><given-names>J.</given-names></name><name><surname>Almagro</surname><given-names>P.</given-names></name><name><surname>Quintano</surname><given-names>J.A.</given-names></name><name><surname>Trigueros</surname><given-names>J.A.</given-names></name><name><surname>Cos&#x000ed;o</surname><given-names>B.G.</given-names></name><name><surname>Casanova</surname><given-names>C.</given-names></name><name><surname>Antonio Riesco</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC)</article-title><source>Arch. Bronconeumol.</source><year>2012</year><volume>48</volume><issue>Suppl. 1</issue><fpage>2</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">23116901</pub-id></element-citation></ref><ref id="B25-medsci-06-00049"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>J.R.</given-names></name><name><surname>Vestbo</surname><given-names>J.</given-names></name><name><surname>Anzueto</surname><given-names>A.</given-names></name><name><surname>Locantore</surname><given-names>N.</given-names></name><name><surname>M&#x000fc;llerova</surname><given-names>H.</given-names></name><name><surname>Tal-Singer</surname><given-names>R.</given-names></name><name><surname>Miller</surname><given-names>B.</given-names></name><name><surname>Lomas</surname><given-names>D.A.</given-names></name><name><surname>Agust&#x000ed;</surname><given-names>A.</given-names></name><name><surname>Macnee</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators Susceptibility to exacerbation in chronic obstructive pulmonary disease</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>1128</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0909883</pub-id><pub-id pub-id-type="pmid">20843247</pub-id></element-citation></ref><ref id="B26-medsci-06-00049"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodruff</surname><given-names>P.G.</given-names></name><name><surname>Agust&#x000ed;</surname><given-names>A.</given-names></name><name><surname>Roche</surname><given-names>N.</given-names></name><name><surname>Singh</surname><given-names>D.</given-names></name><name><surname>Martinez</surname><given-names>F.J.</given-names></name></person-group><article-title>Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: Making progress towards personalised management</article-title><source>Lancet</source><year>2015</year><volume>385</volume><fpage>1789</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)60693-6</pub-id><pub-id pub-id-type="pmid">25943943</pub-id></element-citation></ref><ref id="B27-medsci-06-00049"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bafadhel</surname><given-names>M.</given-names></name><name><surname>McKenna</surname><given-names>S.</given-names></name><name><surname>Terry</surname><given-names>S.</given-names></name><name><surname>Mistry</surname><given-names>V.</given-names></name><name><surname>Reid</surname><given-names>C.</given-names></name><name><surname>Haldar</surname><given-names>P.</given-names></name><name><surname>McCormick</surname><given-names>M.</given-names></name><name><surname>Haldar</surname><given-names>K.</given-names></name><name><surname>Kebadze</surname><given-names>T.</given-names></name><name><surname>Duvoix</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Acute Exacerbations of Chronic Obstructive Pulmonary Disease</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2011</year><volume>184</volume><fpage>662</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1164/rccm.201104-0597OC</pub-id><pub-id pub-id-type="pmid">21680942</pub-id></element-citation></ref><ref id="B28-medsci-06-00049"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Hao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Gibson</surname><given-names>P.G.</given-names></name></person-group><article-title>Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e57678</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0057678</pub-id><pub-id pub-id-type="pmid">23741289</pub-id></element-citation></ref><ref id="B29-medsci-06-00049"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saetta</surname><given-names>M.</given-names></name><name><surname>Di Stefano</surname><given-names>A.</given-names></name><name><surname>Maestrelli</surname><given-names>P.</given-names></name><name><surname>Turato</surname><given-names>G.</given-names></name><name><surname>Ruggieri</surname><given-names>M.P.</given-names></name><name><surname>Roggeri</surname><given-names>A.</given-names></name><name><surname>Calcagni</surname><given-names>P.</given-names></name><name><surname>Mapp</surname><given-names>C.E.</given-names></name><name><surname>Ciaccia</surname><given-names>A.</given-names></name><name><surname>Fabbri</surname><given-names>L.M.</given-names></name></person-group><article-title>Airway eosinophilia in chronic bronchitis during exacerbations</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>1994</year><volume>150</volume><fpage>1646</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.150.6.7952628</pub-id><pub-id pub-id-type="pmid">7952628</pub-id></element-citation></ref><ref id="B30-medsci-06-00049"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brightling</surname><given-names>C.E.</given-names></name><name><surname>McKenna</surname><given-names>S.</given-names></name><name><surname>Hargadon</surname><given-names>B.</given-names></name><name><surname>Birring</surname><given-names>S.</given-names></name><name><surname>Green</surname><given-names>R.</given-names></name><name><surname>Siva</surname><given-names>R.</given-names></name><name><surname>Berry</surname><given-names>M.</given-names></name><name><surname>Parker</surname><given-names>D.</given-names></name><name><surname>Monteiro</surname><given-names>W.</given-names></name><name><surname>Pavord</surname><given-names>I.D.</given-names></name><etal/></person-group><article-title>Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>2005</year><volume>60</volume><fpage>193</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1136/thx.2004.032516</pub-id><pub-id pub-id-type="pmid">15741434</pub-id></element-citation></ref><ref id="B31-medsci-06-00049"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pizzichini</surname><given-names>E.</given-names></name><name><surname>Pizzichini</surname><given-names>M.M.</given-names></name><name><surname>Gibson</surname><given-names>P.</given-names></name><name><surname>Parameswaran</surname><given-names>K.</given-names></name><name><surname>Gleich</surname><given-names>G.J.</given-names></name><name><surname>Berman</surname><given-names>L.</given-names></name><name><surname>Dolovich</surname><given-names>J.</given-names></name><name><surname>Hargreave</surname><given-names>F.E.</given-names></name></person-group><article-title>Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>1998</year><volume>158</volume><fpage>1511</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.158.5.9804028</pub-id><pub-id pub-id-type="pmid">9817701</pub-id></element-citation></ref><ref id="B32-medsci-06-00049"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siva</surname><given-names>R.</given-names></name><name><surname>Green</surname><given-names>R.H.</given-names></name><name><surname>Brightling</surname><given-names>C.E.</given-names></name><name><surname>Shelley</surname><given-names>M.</given-names></name><name><surname>Hargadon</surname><given-names>B.</given-names></name><name><surname>McKenna</surname><given-names>S.</given-names></name><name><surname>Monteiro</surname><given-names>W.</given-names></name><name><surname>Berry</surname><given-names>M.</given-names></name><name><surname>Parker</surname><given-names>D.</given-names></name><name><surname>Wardlaw</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial</article-title><source>Eur. Respir. J.</source><year>2007</year><volume>29</volume><fpage>906</fpage><lpage>913</lpage><pub-id pub-id-type="pmid">17301099</pub-id></element-citation></ref><ref id="B33-medsci-06-00049"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bafadhel</surname><given-names>M.</given-names></name><name><surname>Saha</surname><given-names>S.</given-names></name><name><surname>Siva</surname><given-names>R.</given-names></name><name><surname>McCormick</surname><given-names>M.</given-names></name><name><surname>Monteiro</surname><given-names>W.</given-names></name><name><surname>Rugman</surname><given-names>P.</given-names></name><name><surname>Dodson</surname><given-names>P.</given-names></name><name><surname>Pavord</surname><given-names>I.D.</given-names></name><name><surname>Newbold</surname><given-names>P.</given-names></name><name><surname>Brightling</surname><given-names>C.E.</given-names></name></person-group><article-title>Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD</article-title><source>Respiration</source><year>2009</year><volume>78</volume><fpage>256</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1159/000221902</pub-id><pub-id pub-id-type="pmid">19478474</pub-id></element-citation></ref><ref id="B34-medsci-06-00049"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeh</surname><given-names>K.M.</given-names></name><name><surname>Beier</surname><given-names>J.</given-names></name><name><surname>Kornmann</surname><given-names>O.</given-names></name><name><surname>Mander</surname><given-names>A.</given-names></name><name><surname>Buhl</surname><given-names>R.</given-names></name></person-group><article-title>Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD</article-title><source>Chest</source><year>2003</year><volume>123</volume><fpage>778</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1378/chest.123.3.778</pub-id><pub-id pub-id-type="pmid">12628878</pub-id></element-citation></ref><ref id="B35-medsci-06-00049"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negewo</surname><given-names>N.A.</given-names></name><name><surname>McDonald</surname><given-names>V.M.</given-names></name><name><surname>Baines</surname><given-names>K.J.</given-names></name><name><surname>Wark</surname><given-names>P.A.</given-names></name><name><surname>Simpson</surname><given-names>J.L.</given-names></name><name><surname>Jones</surname><given-names>P.W.</given-names></name><name><surname>Gibson</surname><given-names>P.G.</given-names></name></person-group><article-title>Peripheral blood eosinophils: A surrogate marker for airway eosinophilia in stable COPD</article-title><source>COPD</source><year>2016</year><volume>11</volume><fpage>1495</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.2147/COPD.S100338</pub-id><pub-id pub-id-type="pmid">27445469</pub-id></element-citation></ref><ref id="B36-medsci-06-00049"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascoe</surname><given-names>S.</given-names></name><name><surname>Locantore</surname><given-names>N.</given-names></name><name><surname>Dransfield</surname><given-names>M.T.</given-names></name><name><surname>Barnes</surname><given-names>N.C.</given-names></name><name><surname>Pavord</surname><given-names>I.D.</given-names></name></person-group><article-title>Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials</article-title><source>Lancet Respir. Med.</source><year>2015</year><volume>3</volume><fpage>435</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(15)00106-X</pub-id><pub-id pub-id-type="pmid">25878028</pub-id></element-citation></ref><ref id="B37-medsci-06-00049"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavord</surname><given-names>I.D.</given-names></name><name><surname>Lettis</surname><given-names>S.</given-names></name><name><surname>Locantore</surname><given-names>N.</given-names></name><name><surname>Pascoe</surname><given-names>S.</given-names></name><name><surname>Jones</surname><given-names>P.W.</given-names></name><name><surname>Wedzicha</surname><given-names>J.A.</given-names></name><name><surname>Barnes</surname><given-names>N.C.</given-names></name></person-group><article-title>Blood eosinophils and inhaled corticosteroid/long-acting &#x003b2;-2 agonist efficacy in COPD</article-title><source>Thorax</source><year>2016</year><volume>71</volume><fpage>118</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2015-207021</pub-id><pub-id pub-id-type="pmid">26585525</pub-id></element-citation></ref><ref id="B38-medsci-06-00049"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>J.M.</given-names></name><name><surname>Pace</surname><given-names>H.A.</given-names></name><name><surname>Ladesich</surname><given-names>J.B.</given-names></name><name><surname>Simon</surname><given-names>S.D.</given-names></name></person-group><article-title>Evaluation of the Impact of Corticosteroid Dose on the Incidence of Hyperglycemia in Hospitalized Patients with an Acute Exacerbation of Chronic Obstructive Pulmonary Disease</article-title><source>Hosp. Pharm.</source><year>2016</year><volume>51</volume><fpage>296</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1310/hpj5104-296</pub-id><pub-id pub-id-type="pmid">27303077</pub-id></element-citation></ref><ref id="B39-medsci-06-00049"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e9;nard-Laribi&#x000e8;re</surname><given-names>A.</given-names></name><name><surname>Pariente</surname><given-names>A.</given-names></name><name><surname>Pambrun</surname><given-names>E.</given-names></name><name><surname>B&#x000e9;gaud</surname><given-names>B.</given-names></name><name><surname>Fardet</surname><given-names>L.</given-names></name><name><surname>Noize</surname><given-names>P.</given-names></name></person-group><article-title>Prevalence and prescription patterns of oral glucocorticoids in adults: A retrospective cross-sectional and cohort analysis in France</article-title><source>BMJ Open</source><year>2017</year><volume>7</volume><fpage>e015905</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2017-015905</pub-id><pub-id pub-id-type="pmid">28760791</pub-id></element-citation></ref><ref id="B40-medsci-06-00049"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bafadhel</surname><given-names>M.</given-names></name><name><surname>McKenna</surname><given-names>S.</given-names></name><name><surname>Terry</surname><given-names>S.</given-names></name><name><surname>Mistry</surname><given-names>V.</given-names></name><name><surname>Pancholi</surname><given-names>M.</given-names></name><name><surname>Venge</surname><given-names>P.</given-names></name><name><surname>Lomas</surname><given-names>D.A.</given-names></name><name><surname>Barer</surname><given-names>M.R.</given-names></name><name><surname>Johnston</surname><given-names>S.L.</given-names></name><name><surname>Pavord</surname><given-names>I.D.</given-names></name><etal/></person-group><article-title>Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2012</year><volume>186</volume><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1164/rccm.201108-1553OC</pub-id><pub-id pub-id-type="pmid">22447964</pub-id></element-citation></ref><ref id="B41-medsci-06-00049"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bafadhel</surname><given-names>M.</given-names></name><name><surname>Davies</surname><given-names>L.</given-names></name><name><surname>Calverley</surname><given-names>P.M.A.</given-names></name><name><surname>Aaron</surname><given-names>S.D.</given-names></name><name><surname>Brightling</surname><given-names>C.E.</given-names></name><name><surname>Pavord</surname><given-names>I.D.</given-names></name></person-group><article-title>Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis</article-title><source>Eur. Respir. J.</source><year>2014</year><volume>44</volume><fpage>789</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1183/09031936.00062614</pub-id><pub-id pub-id-type="pmid">24925917</pub-id></element-citation></ref><ref id="B42-medsci-06-00049"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>P.G.</given-names></name></person-group><article-title>Variability of blood eosinophils as a biomarker in asthma and COPD</article-title><source>Respirology</source><year>2018</year><volume>23</volume><fpage>12</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1111/resp.13200</pub-id><pub-id pub-id-type="pmid">29052302</pub-id></element-citation></ref><ref id="B43-medsci-06-00049"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastie</surname><given-names>A.T.</given-names></name><name><surname>Martinez</surname><given-names>F.J.</given-names></name><name><surname>Curtis</surname><given-names>J.L.</given-names></name><name><surname>Doerschuk</surname><given-names>C.M.</given-names></name><name><surname>Hansel</surname><given-names>N.N.</given-names></name><name><surname>Christenson</surname><given-names>S.</given-names></name><name><surname>Putcha</surname><given-names>N.</given-names></name><name><surname>Ortega</surname><given-names>V.E.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Barr</surname><given-names>R.G.</given-names></name><etal/></person-group><article-title>SPIROMICS investigators. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: An analysis of the SPIROMICS cohort</article-title><source>Lancet Respir.</source><year>2017</year><volume>5</volume><fpage>956</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(17)30432-0</pub-id></element-citation></ref><ref id="B44-medsci-06-00049"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bafadhel</surname><given-names>M.</given-names></name></person-group><article-title>Eosinophils in COPD: Are we nearly there yet?</article-title><source>Lancet Respir.</source><year>2017</year><volume>5</volume><fpage>913</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(17)30445-9</pub-id></element-citation></ref><ref id="B45-medsci-06-00049"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duman</surname><given-names>D.</given-names></name><name><surname>Aksoy</surname><given-names>E.</given-names></name><name><surname>Agca</surname><given-names>M.C.</given-names></name><name><surname>Kocak</surname><given-names>N.D.</given-names></name><name><surname>Ozmen</surname><given-names>I.</given-names></name><name><surname>Akturk</surname><given-names>U.A.</given-names></name><name><surname>Gungor</surname><given-names>S.</given-names></name><name><surname>Tepetam</surname><given-names>F.M.</given-names></name><name><surname>Eroglu</surname><given-names>S.A.</given-names></name><name><surname>Oztas</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia</article-title><source>COPD</source><year>2015</year><volume>10</volume><fpage>2469</fpage><lpage>2478</lpage><pub-id pub-id-type="doi">10.2147/COPD.S90330</pub-id><pub-id pub-id-type="pmid">26648709</pub-id></element-citation></ref><ref id="B46-medsci-06-00049"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>K.</given-names></name><name><surname>Camargo</surname><given-names>C.A.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD</article-title><source>Respirology</source><year>2015</year><volume>21</volume><fpage>761</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1111/resp.12724</pub-id><pub-id pub-id-type="pmid">26699685</pub-id></element-citation></ref><ref id="B47-medsci-06-00049"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salt&#x000fc;rk</surname><given-names>C.</given-names></name><name><surname>Karakurt</surname><given-names>Z.</given-names></name><name><surname>Adiguzel</surname><given-names>N.</given-names></name><name><surname>Kargin</surname><given-names>F.</given-names></name><name><surname>Sari</surname><given-names>R.</given-names></name><name><surname>Celik</surname><given-names>M.E.</given-names></name><name><surname>Takir</surname><given-names>H.B.</given-names></name><name><surname>Tuncay</surname><given-names>E.</given-names></name><name><surname>Sogukpinar</surname><given-names>O.</given-names></name><name><surname>Ciftaslan</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit?</article-title><source>COPD</source><year>2015</year><volume>10</volume><fpage>1837</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.2147/COPD.S88058</pub-id><pub-id pub-id-type="pmid">26392758</pub-id></element-citation></ref><ref id="B48-medsci-06-00049"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serafino-Agrusa</surname><given-names>L.</given-names></name><name><surname>Scichilone</surname><given-names>N.</given-names></name><name><surname>Spatafora</surname><given-names>M.</given-names></name><name><surname>Battaglia</surname><given-names>S.</given-names></name></person-group><article-title>Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: A case-control study</article-title><source>Pulm. Pharmacol. Ther.</source><year>2016</year><volume>37</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.pupt.2016.03.004</pub-id><pub-id pub-id-type="pmid">26996272</pub-id></element-citation></ref><ref id="B49-medsci-06-00049"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couillard</surname><given-names>S.</given-names></name><name><surname>Lariv&#x000e9;e</surname><given-names>P.</given-names></name><name><surname>Courteau</surname><given-names>J.</given-names></name><name><surname>Vanasse</surname><given-names>A.</given-names></name></person-group><article-title>Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions</article-title><source>Chest</source><year>2017</year><volume>151</volume><fpage>366</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2016.10.003</pub-id><pub-id pub-id-type="pmid">27746201</pub-id></element-citation></ref><ref id="B50-medsci-06-00049"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorn</surname><given-names>G.W.</given-names></name><name><surname>Renold</surname><given-names>A.E.</given-names></name><name><surname>Wilson</surname><given-names>D.L.</given-names></name><name><surname>Frawley</surname><given-names>T.F.</given-names></name><name><surname>Jenkins</surname><given-names>D.</given-names></name><name><surname>Garc&#x000ed;a-Reyes</surname><given-names>J.</given-names></name><name><surname>Forsham</surname><given-names>P.H.</given-names></name></person-group><article-title>Clinical studies on the activity of orally administered cortisone</article-title><source>N. Engl. J. Med.</source><year>1951</year><volume>245</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1056/NEJM195110112451501</pub-id><pub-id pub-id-type="pmid">14875208</pub-id></element-citation></ref><ref id="B51-medsci-06-00049"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>Y.P.</given-names></name><name><surname>Uil</surname><given-names>S.M.</given-names></name><name><surname>Grotjohan</surname><given-names>H.P.</given-names></name><name><surname>Postma</surname><given-names>D.S.</given-names></name><name><surname>Kerstjens</surname><given-names>H.A.</given-names></name><name><surname>van den Berg</surname><given-names>J.W.</given-names></name></person-group><article-title>Oral or IV Prednisolone in the Treatment of COPD Exacerbations</article-title><source>Chest</source><year>2018</year><volume>132</volume><fpage>1741</fpage><lpage>1747</lpage><pub-id pub-id-type="doi">10.1378/chest.07-0208</pub-id><pub-id pub-id-type="pmid">17646228</pub-id></element-citation></ref><ref id="B52-medsci-06-00049"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>N.W.</given-names></name><name><surname>McPherson</surname><given-names>G.C.</given-names></name><name><surname>Ramsay</surname><given-names>C.R.</given-names></name><name><surname>Campbell</surname><given-names>M.K.</given-names></name></person-group><article-title>The method of minimization for allocation to clinical trials. a review</article-title><source>Control Clin. Trials</source><year>2002</year><volume>23</volume><fpage>662</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/S0197-2456(02)00242-8</pub-id><pub-id pub-id-type="pmid">12505244</pub-id></element-citation></ref><ref id="B53-medsci-06-00049"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivapalan</surname><given-names>P.</given-names></name><name><surname>Moberg</surname><given-names>M.</given-names></name><name><surname>Ekl&#x000f6;f</surname><given-names>J.</given-names></name><name><surname>Janner</surname><given-names>J.</given-names></name><name><surname>Vestbo</surname><given-names>J.</given-names></name><name><surname>Laub</surname><given-names>R.R.</given-names></name><name><surname>Browatzki</surname><given-names>A.</given-names></name><name><surname>Armbruster</surname><given-names>K.</given-names></name><name><surname>Wilcke</surname><given-names>J.T.</given-names></name><name><surname>Seersholm</surname><given-names>N.</given-names></name><etal/></person-group><article-title>A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations&#x02014;The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol</article-title><source>BMC Pulm. Med.</source><year>2017</year><volume>17</volume><elocation-id>114</elocation-id><pub-id pub-id-type="doi">10.1186/s12890-017-0458-7</pub-id><pub-id pub-id-type="pmid">28810909</pub-id></element-citation></ref><ref id="B54-medsci-06-00049"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcos</surname><given-names>P.J.</given-names></name><name><surname>Nieto-Codesido</surname><given-names>I.</given-names></name><name><surname>de Jorge Dominguez-Pazos</surname><given-names>S.</given-names></name><name><surname>Huerta</surname><given-names>A.</given-names></name><name><surname>M&#x000e1;rquez</surname><given-names>E.</given-names></name><name><surname>Maiso</surname><given-names>A.</given-names></name><name><surname>Verdeal</surname><given-names>R.</given-names></name><name><surname>Otero-Gonzalez</surname><given-names>I.</given-names></name><name><surname>Blanco-Aparicio</surname><given-names>M.</given-names></name><name><surname>Montero-Mart&#x000ed;nez</surname><given-names>C.</given-names></name></person-group><article-title>Treatment With Systemic Steroids in Severe Chronic Obstructive Pulmonary Disease Exacerbations: Use of Short Regimens in Routine Clinical Practice and Their Impact on Hospital Stay</article-title><source>Arch. Bronconeumol.</source><year>2017</year><volume>53</volume><fpage>611</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.arbres.2017.03.012</pub-id><pub-id pub-id-type="pmid">28461091</pub-id></element-citation></ref><ref id="B55-medsci-06-00049"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P.H.</given-names></name><name><surname>Cheng</surname><given-names>S.L.</given-names></name><name><surname>Wang</surname><given-names>H.C.</given-names></name><name><surname>Chang</surname><given-names>H.T.</given-names></name><name><surname>Hsu</surname><given-names>Y.L.</given-names></name><name><surname>Chen</surname><given-names>Y.S.</given-names></name><name><surname>Chang</surname><given-names>C.Y.</given-names></name></person-group><article-title>Systemic steroids in acute exacerbation of COPD&#x02014;From guidelines to bedside</article-title><source>Int. J. Clin. Pharmacol. Ther.</source><year>2012</year><volume>49</volume><fpage>705</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.5414/CP201588</pub-id></element-citation></ref><ref id="B56-medsci-06-00049"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M.</given-names></name></person-group><article-title>Medicina basada en la no-evidencia: El ejemplo del uso de los corticosteroides sist&#x000e9;micos en la agudizaci&#x000f3;n de la EPOC</article-title><source>Revista Cl&#x000ed;nica Espa&#x000f1;ola</source><year>2017</year><volume>217</volume><fpage>520</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.rce.2017.09.007</pub-id><pub-id pub-id-type="pmid">29055656</pub-id></element-citation></ref><ref id="B57-medsci-06-00049"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rueda-Camino</surname><given-names>J.A.</given-names></name><name><surname>Bernal-Bello</surname><given-names>D.</given-names></name><name><surname>Canora-Lebrato</surname><given-names>J.</given-names></name><name><surname>Vel&#x000e1;zquez-R&#x000ed;os</surname><given-names>L.</given-names></name><name><surname>de Viedma-Garc&#x000ed;a</surname><given-names>V.G.</given-names></name><name><surname>Guerrero-Santill&#x000e1;n</surname><given-names>M.</given-names></name><name><surname>Duarte-Mill&#x000e1;n</surname><given-names>M.A.</given-names></name><name><surname>Crist&#x000f3;bal-Bilbao</surname><given-names>R.</given-names></name><name><surname>Zapatero-Gaviria</surname><given-names>A.</given-names></name></person-group><article-title>Dosis altas de corticoides sist&#x000e9;micos en pacientes ingresados por exacerbaci&#x000f3;n de enfermedad pulmonar obstructiva cr&#x000f3;nica. Un estudio de cohortes</article-title><source>Revista Cl&#x000ed;nica Espa&#x000f1;ola</source><year>2017</year><volume>217</volume><fpage>504</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/j.rce.2017.07.012</pub-id><pub-id pub-id-type="pmid">28865758</pub-id></element-citation></ref><ref id="B58-medsci-06-00049"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcos</surname><given-names>P.J.</given-names></name><name><surname>Huerta</surname><given-names>A.</given-names></name><name><surname>M&#x000e1;rquez-Mart&#x000ed;n</surname><given-names>E.</given-names></name></person-group><article-title>2014 GesEPOC and Systemic Steroids in chronic obstructive pulmonary disease (COPD) Exacerbation: An Update</article-title><source>Arch. Bronconeumol.</source><year>2015</year><volume>51</volume><fpage>360</fpage><pub-id pub-id-type="doi">10.1016/j.arbres.2014.05.007</pub-id><pub-id pub-id-type="pmid">25022785</pub-id></element-citation></ref><ref id="B59-medsci-06-00049"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanania</surname><given-names>N.A.</given-names></name><name><surname>Sharma</surname><given-names>G.</given-names></name><name><surname>Sharafkhaneh</surname><given-names>A.</given-names></name></person-group><article-title>COPD in the elderly patient</article-title><source>Semin. Respir. Crit. Care Med.</source><year>2010</year><volume>31</volume><fpage>596</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1055/s-0030-1265900</pub-id><pub-id pub-id-type="pmid">20941660</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="medsci-06-00049-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">medsci-06-00049-t001_Table 1</object-id><label>Table 1</label><caption><p>Most relevant studies regarding the efficacy of systemic corticosteroids (SC).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Setting</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Regimen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cumulated Dosage<break/>(Prednisone, mg)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SC<break/>Total Days</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bullard [<xref rid="B12-medsci-06-00049" ref-type="bibr">12</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">138</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Emergency Department</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 1: 100 mg IV hydrocortisone/4 h x 96 h + 4 days oral prednisone 40 mg (5&#x02013;8 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">640&#x02013;760</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 2: Placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Niewoehner [<xref rid="B13-medsci-06-00049" ref-type="bibr">13</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">147</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inpatient</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 1: Methylprednisolone 125 mg/6 h for 72 h, followed by oral prednisone: 60 mg on study days 4 through 7, 40 mg on days 8 through 11, 20 mg on days 12 through 43, 10 mg on days 44 through 50, and 5 mg on days 51 through 57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2985</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 2: Methylprednisolone 125 mg/6 h for 72 h, followed by oral prednisone: 60 mg on days 4 through 7, 40 mg on days 8 through 11, and 20 mg on days 12 through 15, and placebo from study days 16 through 57 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2355</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 3: Placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Maltais [<xref rid="B14-medsci-06-00049" ref-type="bibr">14</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">199</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inpatient</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 1: Prednisone 30 mg/12 h </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">210</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 2: Nebulized budesonide 2 mg/6 h for 72 h, followed 2000 mcg/d of inhaled budesonide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 3: Placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Aaron [<xref rid="B15-medsci-06-00049" ref-type="bibr">15</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">147</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Outpatient</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 1: 40 mg oral prednisone/day</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">400 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 2: Placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="3" align="center" valign="middle" colspan="1">Gunen [<xref rid="B16-medsci-06-00049" ref-type="bibr">16</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">159</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inpatient</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 1: IV prednisolone 40 mg/day for days 1&#x02013;15 if not discharged, oral methylprednisolone 32 mg/day for days 11&#x02013;15 if discharged</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">600 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 2: Nebulized budesonide (1500 mg quater in die [q.i.d])</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 3: no inhaled SC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Leuppi [<xref rid="B19-medsci-06-00049" ref-type="bibr">19</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">314</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inpatient/Outpatient</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 1: Methylprednisolone 40 mg on day 1, 40 mg/day days 2 to 5 + placebo days 5&#x02013;14.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">250 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 2: Methylprednisolone 40 mg on day 1, 40 mg/day days 2 to 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">610</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Abroug [<xref rid="B17-medsci-06-00049" ref-type="bibr">17</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">217</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intensive care unit (ICU)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 1: Prednisone 1 mg/kg daily until discharge </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weight-based</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maximum 10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 2: Usual care</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap><table-wrap id="medsci-06-00049-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">medsci-06-00049-t002_Table 2</object-id><label>Table 2</label><caption><p>Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations regarding the treatment of acute exacerbations of COPD with SC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Guideline</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dosage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Duration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Level of Recommendation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Note</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GOLD 2001 [<xref rid="B20-medsci-06-00049" ref-type="bibr">20</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prednisolone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30&#x02013;40 mg/d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10&#x02013;14 days </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The exact dose that should be given is not known, but high doses are associated with a significant risk of side effects Prolonged treatment does not result in a greater efficacy and increases the risk of side effects</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GOLD 2006 [<xref rid="B21-medsci-06-00049" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prednisolone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30&#x02013;40 mg prednisone/d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7&#x02013;10 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GOLD 2014 [<xref rid="B1-medsci-06-00049" ref-type="bibr">1</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prednisone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 mg/d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 days </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nebulized budesonide alone may be an alternative (although more expensive) to oral corticosteroids in the treatment of exacerbations</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GOLD 2017 [<xref rid="B22-medsci-06-00049" ref-type="bibr">22</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prednisone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 mg/d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recent studies suggest that glucocorticoids may be less efficacious in treating acute chronic obstructive pulmonary disease (COPD) exacerbations in patients with lower blood eosinophil levels</td></tr></tbody></table></table-wrap><table-wrap id="medsci-06-00049-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">medsci-06-00049-t003_Table 3</object-id><label>Table 3</label><caption><p>Prevalence of eosinophilia in severe COPD exacerbations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">n</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Design</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Cut-off</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eosinophils<break/>&#x0003e;2%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eosinophils<break/>&#x02265;2%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eosinophils<break/>&#x0003e;300 cells/&#x000b5;L</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hasegawa [<xref rid="B45-medsci-06-00049" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">3084</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">40%</td><td align="center" valign="middle" rowspan="1" colspan="1">17%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Salturk [<xref rid="B46-medsci-06-00049" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">647</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective</td><td align="center" valign="middle" rowspan="1" colspan="1">9.6%</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duman [<xref rid="B44-medsci-06-00049" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1704</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective</td><td align="center" valign="middle" rowspan="1" colspan="1">20.6%</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Serafino-Agrusa [<xref rid="B47-medsci-06-00049" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">132</td><td align="center" valign="middle" rowspan="1" colspan="1">Retrospective</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">15.1%</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Couillard [<xref rid="B48-medsci-06-00049" ref-type="bibr">48</xref>] *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">167</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.9%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>* Cut-off point defined as: Eosinophils &#x02265;2% and/or &#x02265;200 cells/&#x000b5;L of the total leukocyte count.</p></fn></table-wrap-foot></table-wrap></floats-group></article>